相关实验视频
Updated: Jun 21, 2025

Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
二次性细菌性肺炎的死亡率是否增加,因为缺乏有利于解决问题的调解者?
1Retired United States Patent and Trademark Office, San Jose, CA, USA.
病毒感染会削弱肺部免疫力,使二次细菌性肺炎变得更危险. 这些共感染导致的压倒性炎症和免疫抑制可能超过身体的自然解决机制,增加死亡风险.
科学领域:
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
- 肺部病理学 肺部病理学
背景情况:
- 像RSV和流感这样的呼吸道病毒感染会导致严重的结果.
- 二次性细菌性肺炎经常使病毒感染复杂化,增加死亡率.
- 细菌感染通过脂肪酸媒介和炎症反应诱导肺部免疫抑制.
研究的目的:
- 探索同时发生的病毒性和细菌性呼吸道感染中严重结果的机制.
- 了解这些共感染中的炎症和亲解决媒介的作用.
- 为了调查为什么二次细菌性肺炎是特别致命的.
主要方法:
- 对有关呼吸道病毒和细菌共感染的现有文献的审查.
- 脂肪酸媒介体对免疫细胞操纵的分析.
- 检查炎症和促溶解媒介通路.
主要成果:
- 病毒感染导致最初的炎症和免疫抑制.
- 细菌感染加剧了炎症和免疫抑制.
- 特殊的亲解决调解者可能会被严重的共感染所压倒.
结论:
- 同时的病毒和细菌呼吸道感染,由于复合的炎症和免疫抑制,构成重大威胁.
- 身体的解决机制可能不足以对抗严重的共感染引起的病理.
- 需要进一步的研究来了解和潜在地减轻与二次细菌性肺炎相关的高死亡率.
更多相关视频
00:07A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation
Published on: August 30, 2019
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
相关概念视频
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations: